Still on Mounjaro but not losing weight? What's actually going on

Is it the dose — or just the timing?

The first pen of Mounjaro contains 2.5mg of tirzepatide. That dose exists so your body can adjust to the medicine; the nausea and digestive discomfort that many people experience early on tends to be milder at this level. What it isn't is a full therapeutic dose. Most of the trial evidence that showed substantial weight reduction (around 20% of body weight on average at the highest dose in the SURMOUNT-1 trial, published in the New England Journal of Medicine) was generated at doses of 10mg and 15mg, reached after several months of gradual titration.

So if you're in your first four to eight weeks and the number on the scales hasn't shifted much, that's often exactly what the prescribing schedule anticipates. Progress at 2.5mg or 5mg tends to be modest. The question worth bringing to your clinical review is whether you're on track to titrate, not whether the medicine has failed. You can read more about how the timeline typically unfolds on our page covering how long Mounjaro takes to work.

That said, timing isn't the whole story. If you're already past the early stages and you're on Mounjaro but still not losing weight, dose alone rarely explains what's happening.

Could something be quietly cancelling the appetite effect?

Mounjaro slows gastric emptying and reduces appetite signals, but it doesn't make overeating impossible. One pattern that clinicians see regularly is what's sometimes called calorie compensation: the appetite suppression is real, but meals quietly grow in size, snacks creep back in, or high-calorie drinks (smoothies, full-fat lattes, alcohol) add hundreds of kilocalories that don't register as food in the way a meal does.

Sleep and stress are less obvious but clinically significant. Poor sleep raises ghrelin (a hunger hormone) and cortisol, which promotes fat storage particularly around the abdomen. Someone managing shift work, a new baby, or a period of sustained pressure at work may find their body's hormonal environment is actively working against the medicine. This isn't a failure of willpower; it's physiology, and it's worth naming in a clinical review.

Certain medicines can also blunt progress or cause fluid retention that masks fat loss on the scales: some antidepressants, corticosteroids, and antipsychotics are the most commonly cited. A prescriber who knows your full medication list can assess whether this is relevant, which is one reason our clinical team reviews more than just your BMI at each stage.

What does a genuine plateau actually look like?

The body doesn't lose weight in a straight line. It's normal to have two or three weeks where the scales barely shift, then see a sudden drop. Water retention (caused by a salty meal, a hormonal cycle, or even a new exercise routine (muscles hold water as they repair)) can disguise fat loss entirely for a fortnight. This is why weekly weigh-ins at the same time of day, rather than daily checks, tend to give a more useful picture.

A genuine plateau is usually defined as no meaningful weight change over six or more consecutive weeks at a stable, adequate dose, with no obvious dietary or lifestyle explanation. If that matches your situation, the NHS's tirzepatide guidance notes that your prescriber should review whether the current dose and regimen remain appropriate. At nume, every repeat order involves a clinical re-review for exactly this reason, it's not automatic, and stalling is something a prescriber needs to know about.

If the description above sounds familiar, our more detailed guide to not losing weight on Mounjaro walks through the clinical factors in depth. There's also specific guidance for people who find their appetite has disappeared but the scales aren't moving, a surprisingly distinct situation covered on the page about not eating on Mounjaro but not losing weight.

When should you ask for a clinical review rather than waiting it out?

Most plateaus resolve as the dose increases, habits tighten, or the body's set-point adjusts. But some situations warrant a conversation sooner rather than later. If you haven't lost any weight on Mounjaro after 12 weeks at a maintenance dose, if you've gained weight, or if the appetite suppression that was clear in the early weeks seems to have disappeared, these are signals your prescriber needs to hear.

NICE's guidance on tirzepatide (TA1026) notes that if someone loses less than 5% of their body weight after six months at the highest tolerated dose, whether to continue is a clinical decision that should be made in discussion with the prescriber. That's not a threshold to interpret yourself; it's a prompt for a proper review. The same logic applies privately.

Cost is sometimes a factor in people delaying that conversation. If you're weighing up whether treatment still makes sense financially, our page on Mounjaro pricing in the UK sets out the current context plainly. And for a broader view of what treatment involves from the start, our weight-loss treatment overview covers the full picture. When you're ready to speak to a prescriber, you can check your eligibility with a free consultation, no waiting, reviewed the same working day by a GPhC-registered prescriber.